Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial.
about
Oncolytic Replication of E1b-Deleted AdenovirusesChemovirotherapy: combining chemotherapeutic treatment with oncolytic virotherapyAdenovirus vectors for gene therapy, vaccination and cancer gene therapyHistone deacetylase inhibitor trichostatin A enhances the antitumor effect of the oncolytic adenovirus H101 on esophageal squamous cell carcinoma in vitro and in vivo.MEN1 gene replacement therapy reduces proliferation rates in a mouse model of pituitary adenomas.An inventory of shedding data from clinical gene therapy trials.Anti-tumor effect of oncolytic herpes simplex virus G47delta on human nasopharyngeal carcinoma.Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study.Combination of a MDR1-targeted replicative adenovirus and chemotherapy for the therapy of pretreated ovarian cancer.Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives.Increasing the efficacy of oncolytic adenovirus vectorsTransarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC)Oncolytic viruses in the treatment of bladder cancerRecent progress in the battle between oncolytic viruses and tumours.Recent clinical progress in virus-based therapies for cancer.Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress.Adenoviral vector-based strategies for cancer therapy.Adenovirus with DNA Packaging Gene Mutations Increased Virus Release.Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways.The current state of head and neck cancer gene therapy.Adenoviral Vectors Armed with Cell Fusion-Inducing Proteins as Anti-Cancer Agents.Oncolytic (replication-competent) adenoviruses as anticancer agents.p53-targeted cancer pharmacotherapy: move towards small molecule compounds.Oncolytic viruses in head and neck cancer: a new ray of hope in the management protocol.Viral gene therapy for head and neck cancer.Advances in systemic delivery of anti-cancer agents for the treatment of metastatic cancer.Angiogenesis inhibition using an oncolytic herpes simplex virus expressing endostatin in a murine lung cancer model.Combination of oncolytic adenovirus and dacarbazine attenuates antitumor ability against uveal melanoma cells via cell cycle block.Inhibitory effect of Survivin promoter-regulated oncolytic adenovirus carrying P53 gene against gallbladder cancer.RNA interference-mediated knockdown of p21(WAF1) enhances anti-tumor cell activity of oncolytic adenoviruses.Development of an Oncolytic Adenovirus with Enhanced Spread Ability through Repeated UV Irradiation and Cancer SelectionIn vivo magnetic resonance imaging and spectroscopy identifies oncolytic adenovirus responders.Review: Oncolytic virotherapy, updates and future directions.Increased Overall Survival and Decreased Cancer-Specific Mortality in Patients with Hepatocellular Carcinoma Treated by Transarterial Chemoembolization and Human Adenovirus Type-5 Combination Therapy: a Competing Risk Analysis.From Benchtop to Bedside: A Review of Oncolytic Virotherapy.Designer Oncolytic Adenovirus: Coming of Age.
P2860
Q26777406-EF286B12-8F72-46FD-9A11-90A47FFFE24CQ26852345-F1A2201B-C989-4A34-B665-4871E5D8E142Q27001601-314C574F-CAC8-4CA6-B5CC-1ED3C2BBBB95Q30354691-8F3E4FE0-2E34-4ED2-B0BE-64F6907553F3Q30558844-4BFCBB31-936B-409D-9E25-28DFE886B117Q31129957-1EEB2580-FF42-4379-B7EC-0BB7B434BD6EQ33579396-726E5B87-E379-42EC-8722-67BA8CC59E1DQ33919629-39914F18-9681-452A-A96E-DF748CCAC1DAQ34115068-9538A06D-8A08-4E5D-A341-533A4D2FE700Q34415371-891B59CA-4A83-4D0D-9CD4-FAF5B54EDE36Q35261325-3B24AEC5-73D5-412E-AD6F-E6E67D4B1A93Q35809215-097BCFA5-129C-4046-9604-9D875E717516Q36147934-227C3374-012D-4B31-82BA-82A94C08C5BCQ36315580-F193656D-5903-428D-B315-D0833FA6CD9AQ36627242-4D6CA3DF-A654-43ED-B184-004D5381CD94Q36720873-8A06D355-ABDB-4559-81A0-467CD7C3DE85Q37409025-77962E8A-0FCA-42AE-8A8E-482825906D26Q37539305-0DFB9EDF-7BAD-4776-A686-87172E7630E1Q37564490-2F2D1C71-9068-41ED-B0D6-E7A56A1A45B0Q37595513-4F7636B6-60DD-450E-A7B9-467D5E017FBAQ37628219-9E8D3642-B0D7-4DDF-85DF-9EBCC52F75B1Q37687415-52DC07ED-31F0-461E-B304-A145D5BD83B1Q37865050-12F534EA-F7E9-4A49-9F86-16E847AB9985Q38264443-3695DBB9-A6F1-4705-948E-7BF8B9A07C90Q38381706-37DCB365-9C18-42FC-9A8D-8F9DF364690CQ38808823-47D582FF-185F-4A94-8F66-680310AE2921Q39391503-9C6FEE84-0946-42C7-8610-5838136AA48BQ39396223-EF12AFBD-22E2-4F14-A94A-F8D03A412942Q39451790-8F1306CC-5FC1-4C2B-BE36-5F2D95B173B3Q39858149-4E6C9336-36D6-4305-95DF-25488F5E1371Q40695592-A17170B8-843C-4DF0-96FD-CA5A0AB9AEA2Q42254679-045B134E-5791-4AB0-9F22-70BFB432B4BEQ47160989-54F26038-5A14-418A-AC0C-BE4F8480C30FQ50050604-76E5BC37-D834-4D00-BA0F-9028370CA8DAQ53272922-B95385C2-8B4D-492C-9669-5D125FC98B05Q55467684-853523DD-2344-4C75-919A-A149239C85A3
P2860
Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Intra-tumor injection of H101, ...... pilot phase II clinical trial.
@ast
Intra-tumor injection of H101, ...... pilot phase II clinical trial.
@en
type
label
Intra-tumor injection of H101, ...... pilot phase II clinical trial.
@ast
Intra-tumor injection of H101, ...... pilot phase II clinical trial.
@en
prefLabel
Intra-tumor injection of H101, ...... pilot phase II clinical trial.
@ast
Intra-tumor injection of H101, ...... pilot phase II clinical trial.
@en
P2093
P2860
P921
P356
P1476
Intra-tumor injection of H101, ...... pilot phase II clinical trial.
@en
P2093
P2860
P304
P356
10.3748/WJG.V10.I24.3634
P407
P577
2004-12-01T00:00:00Z